International Society for Hemodialysis™ (ISHD)
Hemodialysis UniversityŽ

August 15 - 16, 2014, Chicago, Illinois USA
     HDCN free zone registration is required.
PART TWO. Optimal Volume Management
Hypertension, hypotension, and more frequent dialysis
Peter Kotanko, MD
Dehydration and fluid overload: Where bioimpedance fits in
James Tattersall, MD
Bioimpedance as a practical tool to assist in optimal fluid management in haemodialysis patients
Elizabeth Lindley, PhD
Drs. Kotanko, Tattersall, and Lindley

Peter Kotanko, MD
Research Director
Renal Research Institute
New York

James Tattersall, MBBS
Specialty Doctor in Renal Medicine
Department of Renal Medicine
St. James's University Hospital
Leeds, United Kingdom

Elizabeth Lindley, PhD
Clinical Scientist in Renal Care
Department of Renal Medicine
St. James's University Hospital
Leeds, United Kingdom
The live program on which this Web-based educational activity is based was supported by educational grants from Fresenius Medical Care, Dialysis Centers Inc, Baxter Healthcare, and Amgen. No industry funding was provided for support of the Web-based program.

Program Overview
This program will discuss on clinically important problems in dialysis, including home hemodialysis (prescription and delivery), complexities of anemia management, pathogenesis and implications of newly recognized unique complications of hemodialysis, and the value of reporting and analysis of patient reported outcomes in improving quality of hemodialysis.

The program is also aimed at improving the overall level of hemodialysis, and provide a good platform for learning and engage in international exchanges hemodialysis doctors, nurses and engineers.

Educational Objectives
Upon completion of this activity, the participants should be able to:
  • HOME HEMODIALYSIS: Describe methods used to select and train patients for home hemodialysis, manage vascular access, home modification for home hemodialysis, equipment maintenance, remote monitoring, adequacy, and patient safety.
  • ANEMIA: Discuss best practices regarding management of anemia in hemodialysis patients including indications for transfusions, hemoglobin targets, iron use, and anemia management algorithms.
  • Assess how to recognize the “DARK SIDE OF HEMODIALYSIS”, i.e. hemodialysis complications like myocardial and brain stunning, individualized dialysate temperature and cool dialysate.
  • Evaluate ANALYTICAL TECHNIQUES for reporting patient reported outcomes.
Target Audience
This program is designed for health professionals involved in dialysis programs, primarily nephrologists, nephrology fellows, nephrology nurses and nurse practitioners, and patient care technicians.

Physician and Nursing Credit
Although the live programs were prepared under CME accreditation guidelines, no CME/CE credit is available for participating in this Web-archived activity.

Disclosure Policy
Each speaker has completed and signed a conflict of interest statement. The faculty members' relationship will be disclosed in the course materials.

Peter Kotanko, MD, owns stock in Fresenius Medical Care, and receives a salary from Renal Research Institute. Dr. Kotanko holds patents in the field of dialysis.

James Tattersall, MD, receives consulting fees from Johnson & Johnson, and a salary from Medical Health Informatics Limited.

Elizabeth Lindley, PhD, has no financial relationship to disclose.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program. The information presented at this program represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by, HDCN or the ISHD. Each participant must use his/her personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses. Before prescribing any medicine, primary references and full prescribing information should be consulted.
This website is managed by HDCN, and their printed privacy policy applies to this site.

The policy statements of HDCN are listed on this page.